Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “Sangamo Therapeutics, Inc.”

106 pharma patents match "Sangamo Therapeutics, Inc." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 106
Index total 30,257
Page 1 / 5

Quick answer

This filtered view shows 106 pharmaceutical patents matching "Sangamo Therapeutics, Inc." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

106 results for “Sangamo Therapeutics, Inc.” · 30,257 patents in full index Clear search

  1. US 12318427

    Methods and compositions for modulation of tau proteins

    Sangamo Therapeutics, Inc. · Granted Jun 3, 2025 · Expires May 29, 2045

    granted
  2. US 12139517

    Modulators of chromosome 9 open reading frame 72 gene expression and uses thereof

    Sangamo Therapeutics, Inc. · Granted Nov 12, 2024 · Expires Nov 7, 2044

    granted
  3. US 12043650

    Methods and compositions for modification of a cystic fibrosis transmembrane conductance regulator (CFTR) gene

    Sangamo Therapeutics, Inc. · Granted Jul 23, 2024 · Expires Jul 18, 2044

    granted
  4. US 11981967

    Engineering AAV

    Sangamo Therapeutics, Inc. · Granted May 14, 2024 · Expires May 9, 2044

    granted
  5. US 11920169

    Compositions for linking DNA-binding domains and cleavage domains

    Sangamo Therapeutics, Inc. · Granted Mar 5, 2024 · Expires Feb 29, 2044

    granted
  6. US 11898158

    Methods and compositions for the treatment of lysosomal storage diseases

    Sangamo Therapeutics, Inc. · Granted Feb 13, 2024 · Expires Feb 8, 2044

    granted
  7. US 11857641

    Method for the treatment of mucopolysaccharidosis type I

    Sangamo Therapeutics, Inc. · Granted Jan 2, 2024 · Expires Dec 28, 2043

    granted
  8. US 11859190

    Methods and compositions for regulation of transgene expression

    Sangamo Therapeutics, Inc. · Granted Jan 2, 2024 · Expires Dec 28, 2043

    granted
  9. US 11845965

    Regulation of gene expression using engineered nucleases

    Sangamo Therapeutics, Inc. · Granted Dec 19, 2023 · Expires Dec 14, 2043

    granted
  10. US 11827900

    Engineered target specific nucleases

    Sangamo Therapeutics, Inc. · Granted Nov 28, 2023 · Expires Nov 23, 2043

    granted
  11. US 11793888

    Methods and compositions for engineering immunity

    Sangamo Therapeutics, Inc. · Granted Oct 24, 2023 · Expires Oct 19, 2043

    granted
  12. US 11723952

    Methods and compositions for treating Huntington's Disease

    Sangamo Therapeutics, Inc. · Granted Aug 15, 2023 · Expires Aug 10, 2043

    granted
  13. US 11718834

    Compositions and methods for producing recombinant AAV

    Sangamo Therapeutics, Inc. · Granted Aug 8, 2023 · Expires Aug 3, 2043

    granted
  14. US 11690921

    Delivery of target specific nucleases

    Sangamo Therapeutics, Inc. · Granted Jul 4, 2023 · Expires Jun 29, 2043

    granted
  15. US 11661612

    DNA-binding proteins and uses thereof

    Sangamo Therapeutics, Inc. · Granted May 30, 2023 · Expires May 25, 2043

    granted
  16. US 11661611

    Genetic modification of cytokine inducible SH2-containing protein (CISH) gene

    Sangamo Therapeutics, Inc. · Granted May 30, 2023 · Expires May 25, 2043

    granted
  17. US 11655275

    Methods and compositions for modification of a cystic fibrosis transmembrane conductance regulator (CFTR) gene

    Sangamo Therapeutics, Inc. · Granted May 23, 2023 · Expires May 18, 2043

    granted
  18. US 11649468

    Targeted integration into the PPP1R12C locus

    Sangamo Therapeutics, Inc. · Granted May 16, 2023 · Expires May 11, 2043

    granted
  19. US 11648267

    Methods and compositions for gene inactivation

    Sangamo Therapeutics, Inc. · Granted May 16, 2023 · Expires May 11, 2043

    granted
  20. US 11639504

    Methods and compositions for regulation of transgene expression

    Sangamo Therapeutics, Inc. · Granted May 2, 2023 · Expires Apr 27, 2043

    granted
  21. US 11634463

    Methods and compositions for treating hemophilia

    Sangamo Therapeutics, Inc. · Granted Apr 25, 2023 · Expires Apr 20, 2043

    granted
  22. US 11608492

    Compositions for linking DNA-binding domains and cleavage domains

    Sangamo Therapeutics, Inc. · Granted Mar 21, 2023 · Expires Mar 16, 2043

    granted
  23. US 11591622

    Method of making and using mammalian liver cells for treating hemophilia or lysosomal storage disorder

    Sangamo Therapeutics, Inc. · Granted Feb 28, 2023 · Expires Feb 23, 2043

    granted
  24. US 11512287

    Targeted disruption of T cell and/or HLA receptors

    Sangamo Therapeutics, Inc. · Granted Nov 29, 2022 · Expires Nov 24, 2042

    granted